---
title: "Tempus Announces National Launch of OneOme Pharmacogenomics Testing, Advancing Patient Safety and Precision Medicine"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293476646.md"
description: "Tempus AI, Inc. (NASDAQ: TEM), a tech firm forefront in utilizing AI to enhance precision medicine and patient care, unveiled the nationwide rollout of its OneOme pharmacogenomics (PGx) testing solution. This offering provides in-depth genetic insights to enhance medication safety, dosage, and assessment of toxicity risks. After acquiring OneOme in November 2025, Tempus has seamlessly merged these functions to broaden its extensive precision medicine portfolio."
datetime: "2026-07-22T12:37:26.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293476646.md)
  - [en](https://longbridge.com/en/news/293476646.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293476646.md)
---

# Tempus Announces National Launch of OneOme Pharmacogenomics Testing, Advancing Patient Safety and Precision Medicine

Tempus AI, Inc. (NASDAQ: TEM), a tech firm forefront in utilizing AI to enhance precision medicine and patient care, unveiled the nationwide rollout of its OneOme pharmacogenomics (PGx) testing solution. This offering provides in-depth genetic insights to enhance medication safety, dosage, and assessment of toxicity risks. After acquiring OneOme in November 2025, Tempus has seamlessly merged these functions to broaden its extensive precision medicine portfolio.

### Related Stocks

- [TEM.US](https://longbridge.com/en/quote/TEM.US.md)
- [TEMT.US](https://longbridge.com/en/quote/TEMT.US.md)

## Related News & Research

- [Tempus AI (NASDAQ:TEM) Director David Epstein Sells 370 Shares of Stock](https://longbridge.com/en/news/295018599.md)
- [Tempus AI Stock Slides Friday: What's Driving the Post-Earnings Reset?](https://longbridge.com/en/news/294530583.md)
- [Tempus AI CEO and Chairman Eric Lefkofsky disposes of USD 10.75 million in common shares](https://longbridge.com/en/news/294438460.md)
- [Tempus AI CEO, Data Ryan Fukushima reports disposal of 23,818 common shares worth $1.1 million](https://longbridge.com/en/news/295010864.md)
- [Tempus AI–Personalis Deal: Integration Risks, Rising Costs, and Regulatory Scrutiny Could Undermine Synergy Gains](https://longbridge.com/en/news/294575248.md)